NAS
STOK icon

Nykredit A/S’s Stoke Therapeutics STOK Stock Holding History

Nykredit A/S’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327 Buy
+10
New +$321 ﹤0.01% 1940

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nykredit A/S's STOK Position: Q2 2026 in Review

Nykredit A/S opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 10 shares worth $327. The stake represents ﹤0.01% of the portfolio and ranks #1940 among its holdings.

123 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Nykredit A/S held 10 shares of Stoke Therapeutics worth $327 as of Q2 2026.
  • Stoke Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1940 holding.
  • 123 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.